Bixiye
QP64-23 Medical Drug Update for New to Market Valoctocogene Roxaparvovec (Roctavian, f.k.a. Valrox)
Taariikhda dhaqangalka Barnaamijka: Jul 12, 2023
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1091 - 1100 ee natiijooyinka 3563
Macluumaadka Maaliyadda
Bixiye
commercial-gc-019-professional-and-technical-components-for-applicable-services.pdf
Macluumaadka Maaliyadda
Bixiye
commercial-si-002-bilateral-procedures.pdf
Macluumaadka Maaliyadda
Bixiye
commercial-si-004-modifier-22.pdf
Bixiye
P88-23 New Commercial Reimbursement Policy: New Patient, Effective February 5, 2024
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023
Bixiye
P89-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023
Bixiye
P90-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Cardiology and Radiology Clinical Guideline Updates
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023
Bixiye
P91-23 New Medical, Medical Drug and Behavioral Health Policy Management Updates, Effective February 5, 2024
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023
Bixiye
P92-23 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023
Bixiye
P93-23 Additional Information for Minnesota Health Care Programs (MHCP) Operations Transitioning back to Blue Cross, effective January 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: Des 01, 2023